Instil Bio, Inc. TIL NASDAQ · Healthcare · United States
$5.43 +0.56% +$0.03
Summary
36 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- It passes only 1 of the 9 points of the Piotroski financial health test.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $20.9M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 2
- Hold 6
- Sell 0
Today's price within the analysts' price targets
The average target of $35 is 545% above today's price. 25% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.